▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #296 by analyst upside · 2026-11-13
ZURA
Zura Bio Limited
Healthcare · Market Cap $119M · P/E 0x
ANALYST PRICE TARGET
+545.2%
implied upside to consensus target
Current Price $1.24
Consensus Target $8.0
Bull Target $12.0
Bear Target $5.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $0.93
52-Week High $7.44
YTD Return -77.7%
FUNDAMENTALS
Market Cap $119M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.11
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.93
52-Week High $7.44
Current Price $1.24
Bear Target $5.0
Bull Target $12.0
● Now $1.24 ● Target $8.0
TRADING DATA
Avg Volume 4.2M
YTD Return -77.7%
Analyst Count 5
Consensus Buy
Upside to Target +545.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Zura Bio Limited (ZURA) is currently trading at $1.24 with a Wall Street consensus price target of $8.0, implying potential upside of 545.2% over the next 12 months. 5 analysts currently cover ZURA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $5.0.

ZURA operates in the Healthcare sector with a market capitalisation of $119M. The stock is down 77.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.93 – $7.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush - Reiterated
Outperform → Outperform 2026-08-12 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-12 62% win rate (8 calls)
William Blair ● Initiated
Outperform 2026-07-08 44% win rate (9 calls)
Wedbush reit
Outperform → Outperform 2026-07-01 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-23 33% win rate (6 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-20 14% win rate (7 calls)
Wedbush ● Initiated
Outperform 2026-02-09 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-11-14 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →